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Background: Nitric oxide is a key molecule not only in the cardiovascular system, but also in the
metabolic-endocrine system. The purpose of this study was to examine possible associations of the NOS3 T-786C
polymorphism (rs2070744) with serum lipid levels on the basis of lifestyle factors for tailoring prevention of
dyslipidemia.
Methods: For this cross-sectional study, a total of 2226 subjects aged 35 to 69 years (1084 men and 1142 women)
were selected from Japanese participants in the Japan Multi-Institutional Collaborative Cohort (J-MICC) Study. They
were recruited in eight areas throughout Japan between February 2004 and November 2008.
Results: In a stratified analysis by leisure-time physical activity, the likelihood of hypertriglyceridemia (serum
triglyceride levels ≥ 150 mg/dL) among subjects with the C allele was significantly lower than those without it in
the active group (OR = 0.43, 95% CI = 0.22-0.84 in the fasting group), but not in the sedentary group. A
gene-environment interaction between the T-786C polymorphism and leisure-time physical activity for
hypertriglyceridemia was significant (P = 0.007 in the fasting group). Additionally, serum triglyceride levels
(mean ± SD) across leisure-time physical activity classes decreased significantly only in the TC + CC genotype
group (111 ± 60 mg/dL for sedentary, 95 ± 48 mg/dL for moderately active, 88 ± 44 mg/dL for very active, P for
trend = 0.008 in the fasting group), but not in the TT genotype group. Total cholesterol, high-density lipoprotein
(HDL) cholesterol, and non-HDL cholesterol levels had no significant association with the polymorphism.
Conclusions: This study suggests that the NOS3 T-786C polymorphism modifies the effect of leisure-time physical
activity on serum triglyceride levels.
Keywords: Cross-sectional study, Gene-environment interaction, Hypertriglyceridemia, Lifestyle-related disease,
NOS3, Tailoring preventionIntroduction
Nitric oxide (NO) is an endothelium-derived relaxing
factor, and plays a crucial role in the cardiovascular sys-
tem [1]. NO is synthesized from L-arginine by the nitric
oxide synthase (NOS) [2]. NOS consists of three major
isoforms: neuronal NOS, inducible NOS, and endothe-
lial NOS (eNOS) [2]. eNOS is encoded by NOS3, a gene* Correspondence: h-bata@med.nagoya-u.ac.jp
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distribution, and reproduction in any mediumlocalized on chromosome 7q35-36 [3], and is constitu-
tively expressed in vascular endothelium, blood plate-
lets, and cardiomyocytes [4]. eNOS-derived NO is
involved in regulation of vascular tone and regional
blood flow, suppression of vascular smooth muscle pro-
liferation, and inhibition of monocyte adhesion and
platelet aggregation [5].
Recently, attention has been focused on eNOS-derived
NO as a key molecule, not only in the cardiovascular sys-
tem, but also in the metabolic-endocrine system [5].
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idemia, and a 40% lower insulin-stimulated glucose uptake
than control mice [6]. Similarly, a number of epidemio-
logical studies have shown associations between NOS3
polymorphisms and endocrine-metabolic disorders. Of
these polymorphisms, the NOS3 T-786C polymorphism, a
thymidine to cytosine transition mutation, substantially
reduces the promoter activity of NOS3 in vitro, resulting
in a decrease of endothelial NO production [7]. A case–
control study reported that significantly more hyperten-
sive patients with metabolic syndrome were homozygous
for the C allele than those patients without it [8].
To date, several previous studies have recruited parti-
cipants from the healthy population (n = 310, 233, 142,
118, and 101, respectively) to investigate the relationship
between the T-786C polymorphism and serum lipid
levels [9-13]. However, there has been no large-scale
population-based study that has analyzed the associ-
ation. Provided that gene-environment interactions be-
tween the T-786C polymorphism and lifestyle factors on
serum lipid levels are well established, the polymorphism
may be useful for tailoring prevention of dyslipidemia by
lifestyle modification.
Therefore, the purpose of the present study was to
examine possible associations of the T-786C polymorph-
ism with serum lipid levels on the basis of lifestyle factors
such as obesity, smoking, and leisure-time physical activ-
ity, using cross-sectional data from the Japan Multi-
Institutional Collaborative Cohort (J-MICC) Study. The
study was launched in 2005 to examine gene-environment
interactions in lifestyle-related diseases, especially cancers,
by 10 research teams throughout Japan [14].
Materials and methods
Study subjects
From 4519 subjects recruited between February 2004 and
November 2008 in this cross-sectional study [15], subjects
who met any of the following criteria were excluded: (i)
absence of data about serum lipid levels, physical examin-
ation, lifestyle, DNA genotyping, and blood sampling time
from their last meal (n = 1416); (ii) medical history of dia-
betes mellitus, liver cirrhosis, thyroid disorder, nephrotic
syndrome, and Cushing syndrome (n = 459); (iii) medica-
tion that affects lipid levels (statins, fibrates, β-blockers,
steroids, estrogen preparations, and antiestrogens)
(n = 227); (iv) blood samples taken within two hours from
their last meal (n = 184); (v) living in enrollment areas
where there were no subjects with hypertriglyceridemia in
stratified analysis, making adjustment for enrollment area
impossible (n = 7). The final study group was a total of
2226 subjects (1084 men and 1142 women) from eight
areas (Shizuoka, Aichi, Shiga, Kyoto, Tokushima, Fukuoka,
Saga, and Kagoshima) throughout Japan. Subjects who
fasted for at least 12 hours after their last meal weredefined as fasting. All subjects included in this study pro-
vided written informed consent, and the J-MICC study in-
cluding the current study was approved by the ethics
committee of Nagoya University School of Medicine (ap-
proval No. 253 and 939).
Clinical and laboratory data
At the time of enrollment, anthropometric and blood
pressure measurements, blood samples, and question-
naires were collected from each subject. BMI was calcu-
lated on the basis of measured height and body weight
at each enrollment area. Blood samples were obtained
for analysis of total cholesterol, high-density lipoprotein
(HDL) cholesterol and triglycerides by a standard labora-
tory protocol used in each research team. Non-HDL
cholesterol levels were calculated as total cholesterol
minus HDL cholesterol levels.
Lifestyle factors
The questionnaires investigated lifestyle factors such as
eating habits, smoking status, and leisure-time physical
activity. Eating habits were assessed using a validated
food frequency questionnaire [16]. Fat energy ratio was
calculated by using the following formula: 9 × fat intake
(grams/day)/caloric intake (kcal/day) × 100.
Smoking habits were assessed by smoking status and
cumulative exposure. Smoking status included; never,
former, and current smoking. In former and current
smokers, cumulative smoking exposure was quantified
in terms of pack-years by multiplying the number of
years smoked by the average number of packs per day.
According to pack years, smokers were classified into
three levels: light (< 20 pack-years), moderate (< 40 but
≥ 20 pack-years), and heavy (≥ 40 pack-years).
Leisure-time physical activity was evaluated using the
International Physical Activity Questionnaire (IPAQ)
[17]. IPAQ was developed and validated as an instrument
for cross-national monitoring of physical activity and in-
activity [17]. From the type, frequency of, and time spent
on physical activity during leisure time, the degree of
leisure-time physical activity was calculated as metabolic
equivalent (MET)-minutes/week (MET levels × minutes
of activity/day × days/week) according to IPAQ. The de-
gree of leisure-time physical activity in subjects was clas-
sified into three groups: sedentary (< 600 MET-minutes/
week), moderately active (< 1500 but ≥ 600 MET-minutes/
week), and very active (≥ 1500 MET-minutes/week). In
addition, subjects whose leisure-time physical activity was
600 MET-minutes/week or more were defined as active.
NOS3 genotyping
Each genomic DNA sample was prepared from periph-
eral blood by a BioRobot M48 Workstation (Qiagen
Group, Tokyo, Japan) or an automatic nucleic acid
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Japan). The T-786C polymorphism was genotyped by a
multiplex polymerase chain reaction (PCR)-based In-
vader assay (Third Wave Technologies, Madison, WI,
USA) at the Laboratory for Genotyping Development,
Center for Genomic Medicine, RIKEN, as described pre-
viously [18].
For multiplex PCR, a 180-bp fragment encompassing the
T-786C polymorphism was amplified with the following
primers: 50-TGAAGTGCCTGGAGAGTGC-30 and 50-
CCCACCCTGTCATTCAGTG-30. The amplified fragment
was diluted and used for the Invader assay. Signal inten-
sities that discriminated genotypes were recorded after the
reaction using the ABI7900HT sequence detection system
(Applied Biosystems, Foster City, CA, USA).
Statistical analysis
Chi-squared tests were performed to analyze deviation
of observed genotype frequencies from the Hardy-
Weinberg equilibrium. Differences in the quantitative
data among the genotypes were examined by one-way
ANOVA. Normality was tested by the skewness and kur-
tosis test, and parameters without normal distribution
were analyzed after log-transformation.
Odds ratios (ORs) and 95% confidence intervals (CIs)
for the presence of the C allele for hypertriglyceridemia
(serum triglyceride levels ≥ 150 mg/dL) and P values for
the interaction between the polymorphism and lifestyle
factors for hypertriglyceridemia were calculated by mul-
tiple logistic regression analysis, and adjusted in the fol-
lowing two ways: (model 1) for age (continuous), sex
(male and female), and enrollment area (Shizuoka, Aichi,
Shiga, Kyoto, Tokushima, Fukuoka, Saga, and Kagoshima);
(model 2) for age, sex, enrollment area, BMI (continuous),
fat energy ratio (continuous), smoking habits (never, light,
moderate, and heavy), leisure-time physical activity (sed-
entary, moderately active, and very active), and blood sam-
pling time from last meal (≥ 12 h, 8 h to < 12 h, 4 h to < 8
h, and 2 h to < 4 h). A multiplicative interaction term was
included in the logistic model to test the interactions. The
statistical power among total subjects to detect an OR of
0.50, 0.60, or 0.70 for carriers of the C allele was estimated
to be 99%, 96%, or 73%, respectively (estimated minor al-
lele carriers frequency in a Japanese population without
hypertriglyceridemia = 0.20). Similarly, the powers among
the subgroups examined were 98%, 83%, or 53% for BMI
< 25, 74%, 50%, or 27% for BMI ≥ 25, 97%, 83%, or 53%
for pack-years < 20, 73%, 49%, or 27% for pack-years ≥ 20,
96%, 80%, or 50% for sedentary, and 82%, 58%, or 32% for
active, respectively. In the subgroups stratified by leisure-
time physical activity, our sample size could detect an OR
of 0.50 with more than 80% power.
In addition, serum triglyceride levels were compared
between leisure-time physical activity classes, namely,sedentary, moderately active, and very active. Trends of
serum triglyceride levels across the classes and differ-
ences in serum triglyceride levels between the classes
were tested using multiple linear regression models by
coding 1, 2, or 3 for sedentary, moderately active, and
very active, respectively, as an independent variable with
the same covariates as used in model 2 above. The
dependent variable was the log-transformed value of
serum triglyceride levels. A two-tailed P value of < 0.05
was considered to be statistically significant. All analyses
were conducted using Stata version 11.0 (Stata Corp.,
College Station, TX, USA).
Results
Frequencies of the NOS3 T-786C polymorphism
A total of 19.2% of subjects were carriers of the C allele
(TC + CC), with an allelic frequency of 10.2%. The T-786C
genotype distribution of all subjects followed the Hardy-
Weinberg equilibrium (χ2 = 0.47, P = 0.49, Table 1).
Clinical characteristics of subjects
The characteristics of study subjects by sex are shown in
Table 1. Regarding leisure-time physical activity, males
and females showed a similar distribution. Table 2 sum-
marizes the BMI, blood pressure, and laboratory para-
meters of all subjects by the T-786C genotype. Serum
triglyceride levels were significantly different among the
three genotypes. Total cholesterol, HDL cholesterol, and
non-HDL cholesterol had no significant association with
the polymorphism.
Stratified analysis by lifestyle factors for
hypertriglyceridemia
Multiple logistic regression analysis of an association be-
tween the T-786C polymorphism and hypertriglyceridemia
(serum triglyceride levels ≥ 150 mg/dL) demonstrated that
the ORs for the presence of the C allele for hypertriglyceri-
demia in both the total and fasting group were not signifi-
cant (Table 3).
All subjects were stratified into two subgroups by
BMI, pack-years of smoking, or leisure-time physical ac-
tivity. There was no significant association between the
polymorphism and hypertriglyceridemia in the sub-
groups stratified by BMI or pack-years of smoking. How-
ever, the likelihood of hypertriglyceridemia among
subjects with the C allele was significantly lower than
those without it in the active group. In addition, gene-
environment interactions between the polymorphism
(TC + CC vs. TT) and leisure-time physical activity (ac-
tive vs. sedentary) for hypertriglyceridemia were also sig-
nificant in both the total and fasting group. When
stratified by sex, the interaction was significant only for
females in the fasting group (P = 0.04), and not signifi-
cant for both males and females in the total group.




TT 869 (80.2) 930 (81.4) 1799 (80.8)
TC 202 (18.6) 199 (17.4) 401 (18.0)
CC 13(1.2) 13(11) 26(1.2)
Age (y)
35 to < 40 47(4.3) 54(4.7) 101 (4.5)
40 to < 50 222 (20.5) 236 (20.7) 458 (20.6)
50 to < 60 354 (32.7) 438 (38.4) 792 (35.6)
≥ 60 461 (42.5) 414 (36.3) 875 (39.3)
BMI (kg/m2)
< 25 749 (69.1) 896 (78.5) 1645 (73.9)
25 to < 30 303 (28.0) 212 (18.6) 515 (23.1)
≥ 30 32(3.0) 34 (3.0) 66(3.0)
Fat energy ratio (%)
< 20 584 (53.9) 151 (13.2) 735 (33.0)
20 to < 25 330 (30.4) 364 (31.9) 694 (31.2)
25 to < 30 123 (11.4) 369 (32.3) 492 (22.1)
≥ 30 47 (43) 258 (22.6) 305 (13.7)
Smoking habits (pack-years)
Never 333 (30.7) 1046 (91.6) 1 379 (62.0)
Light (< 20) 245 (22.6) 55 (4.8) 300 (13.5)
Moderate (20 to < 40) 283 (26.1) 35 (3.1) 318 (14.3)
Heavy (≥ 40) 223 (20.6) 6 (0.5) 229 (10.3)
Leisure-time physical activity
(MET-minutes/week)
Sedentary (< 600) 644 (59.4) 705 (61.7) 1 349 (60.6)
Moderately active (600 to
< 1500)
295 (27.2) 305 (26.7) 600 (27.0)
Very active (≥ 1500) 145 (1 3.4) 132 (11.6) 277 (12.4)
Values are presented as n (%).
MET, metabolic equivalent.
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physical activity
Figure 1 shows serum triglyceride levels according to
leisure-time physical activity in the TT and TC + CC
genotype groups. Serum triglyceride levels across leisure-
time physical activity classes decreased significantly only
in the TC + CC genotype group (111 ± 60 mg/dL for
sedentary, 95 ± 48 mg/dL for moderately active, 88 ± 44
mg/dL for very active, P for trend = 0.008 in the fasting
group), but not in the TT genotype group. Moreover, in
the TC + CC genotype group, both the moderately and
very active groups had significantly lower serum trigly-
ceride levels than the sedentary group in the total group
(P = 0.005 for moderately active and P = 0.02 for very
active) and the fasting group (P = 0.04 for moderatelyactive and P = 0.03 for very active). No significant dif-
ference was seen in the TT genotype group.
Discussion
The present study found that gene-environment interac-
tions between the NOS3 T-786C polymorphism and
leisure-time physical activity on serum triglyceride levels
were significant, and that both the moderately and very
active groups had significantly lower serum triglyceride
levels than the sedentary group in the TC + CC geno-
type group, but not in the TT genotype group. This sug-
gests that the presence of the C allele enhances the
beneficial effect of leisure-time physical activity on
serum triglyceride levels. An intervention study showed
that the presence of the C allele did not affect the bene-
ficial effect of exercise in reducing serum triglyceride
levels among postmenopausal women (n = 49) [19], but
the sex difference of this effect was unclear in the
current study.
The genotype distribution of the current study subjects
was very similar to that described previously in 233
Japanese (83.3%, 15.0%, and 1.7% for the TT, TC, and CC
genotypes, respectively) [10]. Compared with Caucasians,
C allele carriers were much less common in Japanese
(32.0%, 52.0%, and 16.0% for the TT, TC, and CC geno-
types in Caucasians, respectively) [20].
Recently, the role of triglycerides in atherosclerotic
diseases was controversial because of the large variation
in triglyceride measurements, and the strong inverse
relationship between HDL cholesterol and triglycerides
[21]. However, large meta-analyses of prospective stu-
dies have reported that triglycerides are an independent
risk factor for coronary heart disease in the general
Western populations, and Asian and Pacific populations
[22,23]. Triglycerides are not directly atherogenic, but
represent an important biomarker of cardiovascular di-
sease risk because of their association with atherogenic
remnant particles and apolipoprotein C-III, a lipopro-
tein lipase (LPL) inhibitor [24]. Therapy with fibrates,
most selective triglyceride-reducing drugs, was reported
to produce a 10% risk reduction for major cardiovascu-
lar events and a 13% relative risk reduction for coronary
heart disease [25].
Triglycerides are frequently associated with lifestyle
factors, one of which is exercise. Aerobic exercise was
reported to cause a 15% to 20% reduction in serum tri-
glycerides when triglyceride levels were over 150 mg/dL
[24]. In rats, exercise induces an increase in LPL mass
and total and heparin-releasable LPL activity in white
skeletal muscle [26]. Interestingly, these beneficial effects
of exercise may involve NO [27]. In vitro, shear stress of
bovine aortic endothelial cells increased the eNOS tran-
scriptional rate and upregulated eNOS mRNA levels
[28]. An experiment using Goto-Kakizaki rats (a model
Table 2 BMI, BP, and laboratory parameters of study subjects by the NOS3 T-786C genotype
Parameters TT (n= 1799) TC (n= 401) CC (n= 26) P valuea
BMI (kg/m2) 23 (21–25) 23 (21–25) 24 (20–26) 0.70
Systolic BP (mm Hg) 126 (113–138) 126 (112–138) 126 (116–138) 0.99
Diastolic BP (mm Hg) 78 (70–85) 78 (70–85) 79 (70–84) 0.99
Total cholesterol (mg/dL) 212 (188–234) 207 (187–235) 207 (182–238) 0.63
HDL cholesterol (mg/dL) 62 (52–74) 62 (52–75) 61 (53–73) 0.57
Non-HDL cholesterol (mg/dL) 147 (125–171) 144 (125–169) 147 (114–175) 0.50
Triglycerides (mg/dL) 99 (71–146) 93 (69–135) 92 (65–193) 0.04
Glucose (mg/dL)b 94 (89–102) 94 (90–101) 93 (87–100) 0.80
HbA1c (%)b 5.1 (4.9-5.3) 5.1 (4.9-5.3) 5.0 (4.8-5.2) 0.75
AST (U/L) 21 (18–25) 21 (17–25) 20 (17–24) 0.17
ALT (U/L) 19 (14–25) 18 (14–25) 1 7 (14–25) 0.56
GGT (U/L) 23 (15–41) 25 (17–39) 24 (16–37) 0.72
Creatinine (mg/dL) 0.76 (0.63-0.90) 0.77 (0.61-0.90) 0.75 (0.67-0.82) 0.90
Uric acid (mg/dL)b 5.1 (4.2-6.0) 5.2 (4.2-6.1) 5.0 (3.9-6.3) 0.97
Values are presented as median (interquartile range).
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BP, blood pressure; GGT , gamma-glutamyl transpeptidase; HbA1c, glycosylated hemoglobin; HDL, high-
density lipoprotein.
a Analyses were done after log-transformation.
b Data were not available; 391 with TT, 73 with TC, and 6 with CC for glucose, 333, 50, and 5 for HbA1c, respectively, and 1 with TT for uric acid.
Table 3 The NOS3 T-786C polymorphism and hypertriglyceridemia (serum triglyceride levels ≥ 150)
TC+CC)vs. TT, modela1 (TC+CC)vs. TT, modelb2
OR 95%CI Interaction OR 95% Interaction
P value P value
Total (n = 2226) 0.80 0.61-1.05 0.78 0.59-1.03
BMI (kg/m2)
< 25 (n = 1645) 0.76 0.54-1.06 0.63 0.75 0.54-1.06 0.55
≥ 25 (n = 581) 0.85 0.53-1.36 0.89 0.55-1.44
Cumulative smoking exposure
Pack-years < 20 (n = 1679) 0.83 0.60-1.16 0.72 0.81 0.58-1.14 0.64
Pack-years ≥ 20 (n = 547) 0.73 0.45-1.18 0.69 0.41-1.13
Leisure-time physical activityc
Sedentary (n = 1349) 1.01 0.72-1.42 0.03 1.03 0.72-1.46 0.01
Active (n = 877) 0.55 0.35-0.88 0.49 0.31-0.80
Fasting (n = 1417) 0.83 0.58-1.18 0.80 0.58-1.16
BMI (kg/m2)
< 25 (n = 1067) 0.76 0.48-1.18 0.68 0.73 0.46-1.14 0.58
≥ 25 (n = 350) 0.90 0.49-1.64 0.92 0.50-1.70
Cumulative smoking exposure
Pack-years < 20 (n = 1059) 0.86 0.54-1.35 0.68 0.81 0.51-1.29 0.74
Pack-years ≥ 20 (n = 358) 0.74 0.42-1.32 0.75 0.41-1.36
Leisure-time physical activityc
Sedentary (n = 872) 1.17 0.76-1.80 0.008 0.18 0.75-1.86 0.007
Active (n = 545) 0.43 0.22-0.83 0.43 0.22-0.84
CI, confidence interval; OR, odds ratio.
a Adjusted for age (continuous), sex (male and female), and enrollment area (Shizuoka, Aichi, Shiga, Kyoto, Tokushima, Fukuoka, Saga and Kagoshima.
b Adjusted for age, sex, enrollment area, BMI (continuous), fat energy ratio (continuous), smoking habits (never, light, moderate, and heavy), leisure-time physical
activity (sedentary, moderate active, and very active), and blood sampling time from last meal (≥ 12 h, 8 h to < 12 h, 4 h to < 8 h, and 2 h to < 4 h).
c Sedentary, metabolic equivalent (MET)-minutes/week < 600; Active, MET-minutes/week ≥ 600.
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Figure 1 Serum triglyceride levels according to leisure-time physical activity by the NOS3 T-786C genotype. Serum triglyceride levels are
presented as mean ± SD. Trends of serum triglyceride levels across leisure-time physical activity classes, namely, sedentary, moderately active, and very
active, and differences in serum triglyceride levels between the classes were tested after adjustment for age (continuous), sex (male and female),
enrollment area (Shizuoka, Aichi, Shiga, Kyoto, Tokushima, Fukuoka, Saga, and Kagoshima), BMI (continuous), fat energy ratio (continuous), smoking
habits (never, light, moderate, and heavy), and blood sampling time from last meal (≥ 12 h, 8 h to < 12 h, 4 h to < 8 h, and 2 h to < 4 h) by multiple
linear regression analysis. Values of serum triglyceride levels were log-transformed before analysis was carried out. * P < 0.05 compared to the
sedentary group in each genotype group.
Higashibata et al. Lipids in Health and Disease 2012, 11:150 Page 6 of 8
http://www.lipidworld.com/content/11/1/150of type 2 diabetes) showed that exercise increased both
the total eNOS expression and the dimer:monomer ratio
in the left ventricle and induced significant increases in
NO production and concomitant decreases in eNOS-
dependent superoxide production [29].
NO can lower serum triglyceride levels by three
mechanisms. Firstly, NO can promote triglyceride me-
tabolism through an increase in blood flow and insulin
to tissues [30]. Insulin and its counterregulation have
been reported to play a central role in triglyceride me-
tabolism by suppression of hepatic production and se-
cretion of triglyceride-rich lipoproteins [31] and
stimulation of LPL activity [32]. Secondly, NO can de-
crease free fatty acid concentration for the synthesis of
triglycerides by promoting the formation of new meta-
bolically active mitochondria [33] and activating carni-
tine palmitoyltransferase 1, an enzyme which transports
activated fatty acids into mitochondria for oxidation
[34]. Thirdly, NO can suppress the synthesis of triglycer-
ides in liver by inhibiting the de novo fatty acid synthesis
through an adenosine monophosphate-activated protein
kinase-dependent inhibition of the activity of acetyl-CoA
carboxylase, which catalyzes the carboxylation of acetyl-
CoA to malonyl-CoA, a key substrate in chain elong-
ation during fatty acid biosynthesis [34].
To date, there has been no experimental study that
has shown the difference in responsiveness to exercise in
NO production among the T-786C genotypes. It has
been reported that a shear stress responsive element islocated near the promoter region of NOS3 between
nucleotides −1600 and −779 [35], but the question of
whether the polymorphism modifies the effect of phys-
ical activity on NO production is controversial. An inter-
vention study showed that six months of aerobic
exercise increased the bioavailability of NO only in sub-
jects with the C allele [36]. In contrast, another study
showed that the increase in NO production in response
to six months exercise was greater in women without
the C allele as compared with those with it [37].
In addition to exercise, the polymorphism has been
reported to modulate the effect of statins, which are 3-
hydroxy-3-methyl-glutaryl-CoA reductase inhibitors [38].
An in vitro experiment demonstrated that fluvastatin aug-
mented eNOS transcriptional activity in human umbilical
vein endothelial cells (HUVECs) containing the CC geno-
type more powerfully than those with the TT genotype.
This effect was due to a decrease in gene expression of
replication protein A1 (RPA1). RPA1 specifically binds to
the C allele and significantly suppresses the transcriptional
activity of NOS3 [39]. This finding was supported by an
epidemiological study that showed atorvastatin treatment
increased whole blood nitrite concentrations and attenu-
ated oxidative stress in the CC genotype group, but not in
the TT genotype group [40]. Future studies investigating
the effect of exercise on RPA1 expression by the T-786C
genotype is eagerly anticipated.
The current study had several limitations. To begin
with, the examination was limited to only one NOS3
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other NOS3 polymorphisms, as well as polymorphisms of
other genes that are associated with serum triglyceride
levels. Next, there may have been differences among the
institutions in measurement methods concerning clinical
data. However, such differences may have had a limited
impact on data analysis as enrollment area was added to
the adjustment factors. Finally, physical activity of subjects
was taken into account only during their leisure time, not
all the time, and the effect of physical activity outside of
leisure time may have been confounding.
In conclusion, the present study suggests that the
NOS3 T-786C polymorphism modifies the effect of
leisure-time physical activity on serum triglyceride levels.
Tailoring prevention of hypertriglyceridemia on the basis
of the T-786C genotypes could be achieved, provided
that further studies, including cohort and intervention
studies, validate the results of this cross-sectional study.
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